# Arsenal Biosciences, Inc.

> Arsenal Biosciences (ArsenalBio) is a clinical-stage, programmable cell therapy company in South San Francisco engineering CAR-T cell therapies for solid tumors. By combining CRISPR genome engineering, synthetic biology, high-throughput target discovery and machine learning, it builds 'integrated circuit T cells' that carry logic gates and multiple drug functions to attack tumors while sparing healthy tissue. Founded in 2019 by surgeon-executive Ken Drazan with leading academic immunologists, the company has raised roughly $850M total, including an oversubscribed $325M Series C in 2024 backed by ARCH, NVIDIA's NVentures, Regeneron Ventures and Bristol Myers Squibb.

- **Founded:** 2019
- **Headquarters:** South San Francisco, California, United States
- **Founders:** Ken Drazan (Co-Founder, Chairman & CEO), Kole T. Roybal (Scientific Co-Founder (synthetic biology, UCSF)), Alexander Marson (Scientific Co-Founder (genome engineering, UCSF)), E. John Wherry (Scientific Co-Founder (T cell exhaustion, UPenn)), Brad Bernstein (Scientific Co-Founder (epigenomics, Broad Institute)), W. Nicholas Haining (Co-Founder & Chief Scientific Officer)
- **Team size:** ~200 employees (reduced by roughly half in a September 2025 restructuring)
- **Products:** Integrated Circuit T cell (ICT) platform, AB-1015, AB-2100, AB-3028, AB-4000 series
- **Notable:** Raised an oversubscribed $325M Series C in September 2024 - one of the largest biotech rounds of the year - with NVIDIA, Regeneron and BMS participating., Approximately $850M raised in total funding since founding., Advanced three internally discovered programs (AB-1015, AB-2100, AB-3028) into or toward the clinic across ovarian, kidney and prostate cancers.

## Products & services

- **Integrated Circuit T cell (ICT) platform** — Core technology combining CRISPR-based genome engineering, synthetic DNA cassettes with logic gates, high-throughput target discovery and machine learning to build T cells carrying multiple coordinated drug functions.
- **AB-1015** — First internally discovered T cell therapy; Phase 1 trial for ovarian cancer. Uses an AND logic gate for dual-antigen targeting to limit off-tumor toxicity plus dual shRNA knockdown of FAS and PTPN2 to resist tumor-microenvironment suppression.
- **AB-2100** — Integrated circuit T cell candidate in a Phase 1/2 trial for clear-cell renal cell carcinoma (kidney cancer); first patient dosed in April 2024.
- **AB-3028** — Programmable T cell candidate in development for certain forms of prostate cancer; IND filing planned for end of 2025.
- **AB-4000 series** — Next-generation T cell therapy programs developed under a multi-program collaboration with Bristol Myers Squibb; BMS exercised its exclusive license option in January 2025.

## Achievements

- Raised an oversubscribed $325M Series C in September 2024 - one of the largest biotech rounds of the year - with NVIDIA, Regeneron and BMS participating.
- Approximately $850M raised in total funding since founding.
- Advanced three internally discovered programs (AB-1015, AB-2100, AB-3028) into or toward the clinic across ovarian, kidney and prostate cancers.
- Bristol Myers Squibb exercised its exclusive license option on the AB-4000 series in January 2025.
- Pioneered the 'integrated circuit T cell' approach embedding logic gates and multiple synthetic functions into a single therapy.

## Latest updates

- **2025-09** — Implemented a strategic restructuring reducing roughly half of staff while continuing toward an IND filing for AB-3028 in prostate cancer by year end.
- **2025-01** — Bristol Myers Squibb exercised its exclusive license option for the AB-4000 series, the lead program under the 2020 multi-program collaboration.
- **2024-09** — Closed oversubscribed $325M Series C led by ARCH Venture Partners with NVentures, Regeneron Ventures and others.
- **2024-04** — Dosed first patient in the Phase 1/2 trial of AB-2100 for clear-cell renal cell carcinoma.

## Links

- Website: https://arsenalbio.com
- LinkedIn: http://www.linkedin.com/company/arsenalbio
- Twitter/X: https://twitter.com/arsenalbio
- Facebook: https://facebook.com/ArsenalBio

---

Profile page: https://yespress.io/arsenal-biosciences-inc
Published by YesPress — https://yespress.io
Last updated: 2026-06-16